Brentuximab vedotin - a highly potent Therapy in cutaneous T-Cell-Lymphoma

被引：0
|
作者：
Pax, A. T.
Stadler, R.
机构：
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2014年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [21] Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
    Muniesa, Cristina
    Gallardo, Fernando
    Garcia-Doval, Ignacio
    Teresa Estrach, M.
    Combalia, Andrea
    Morillo-Andujar, Mercedes
    De la Cruz-Vicente, Fatima
    Machan, Salma
    Moya-Martinez, Cristina
    Rovira, Roger
    Sanchez-Gonzalez, Blanca
    Acebo, Elvira
    Amutio, Elena
    Penate, Yeray
    Del Carmen Losada-Castillo, Maria
    Pilar Garcia-Muret, M.
    Iznardo, Helena
    Roman-Curto, Concepcion
    Canueto, Javier
    Fernandez-de-Misa, Ricardo
    Florez, Angeles
    Maria Izu, Rosa
    Torres-Navarro, Ignacio
    Zayas, Ana
    Perez-Paredes, Gema
    Blanes, Mar
    Ignacio Yanguas, J.
    Perez-Ferriols, Amparo
    Callejas-Charavia, Marta
    Luis Ortiz-Romero, Pablo
    Perez-Gil, Amalia
    Prieto-Torres, Lucia
    Gonzalez-Barca, Eva
    Servitje, Octavio
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (01) : 57 - 64
  • [22] Alternate dosing regimens of brentuximab vedotin for CD30+cutaneous T-cell lymphoma
    Lewis, D. J.
    Kim, Y. H.
    Duvic, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : 302 - 303
  • [23] Brentuximab Vedotin in primary cutaneous CD30+large-cell anaplastic T-Cell Lymphoma
    Moritz, R. K. C.
    Patsinakidis, N.
    Terras, S.
    Moellenhoff, K.
    Gambichler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 921 - 921
  • [24] Primary cutaneous follicular Helper T-Cell-Lymphoma
    Berthold, E.
    Enk, A.
    Hassel, J.
    Geissinger, E.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 3 - 3
  • [25] Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry
    Muniesa, C.
    Gallardo, F.
    Garcia-Doval, I.
    Estrach, M. T.
    Combalia, A.
    Morillo-Andujar, M.
    De la Cruz Vicente, F.
    Machan, S.
    Moya-Martinez, C.
    Rovira, R.
    Sanchez-Gonzalez, B.
    Acebo, E.
    Amutio, E.
    Penate, Y.
    Losada-Castillo, M. C.
    Garcia-Muret, M. P.
    Iznardo, H.
    Roman-Curto, C.
    Canueto, J.
    Fernandez de Misa, R.
    Florez, A.
    Izu, R.
    Torres-Navarro, I.
    Zayas, A.
    Perez-Paredes, G.
    Blanes, M.
    Yanguas, J. I.
    Perez-Ferriols, A.
    Callejas-Charavia, M.
    Ortiz-Romero, Pl
    Perez-Gil, A.
    Prieto-Torres, L.
    Gonzalez-Barca, E.
    Servitje, O.
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : S40 - S41
  • [26] Complete healing of basal cell carcinoma under bendamustine and brentuximab vedotin therapy in a patient with cutaneous lymphoma
    Baykal, Can
    Kutlay, Armagan
    Buyukbabani, Nesimi
    DERMATOLOGIC THERAPY, 2019, 32 (04)
  • [27] Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
    Sahin, Mustafa
    Miskioglu, Mine
    Inanir, Isil
    Akar, Hikmet
    Nese, Nalan
    Temiz, Peyker
    Aydogdu, Ismet
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (01) : 85 - 87
  • [28] Primary Cutaneous T-Cell-Lymphoma versus primayr nodals T-Cell-Lymphoma with Secondary Skin Infiltration - a Diagnostic Challenge
    Bischof, L.
    Riesenbeck, M.
    Huettmann, A.
    Schadendorf, D.
    Hillen, U.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 43 - 43
  • [29] Experiences in the therapy of advanced cutaneous T-cell-lymphoma with vorinostat, histondeacetylase inhibitor (zolinza®)
    Stadler, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 : 236 - 236
  • [30] Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine
    Voruz, Sophie
    de Leval, Laurence
    Cairoli, Anne
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
12345